Aurora Cannabis (ACB) Cash from Investing Activities (2017 - 2025)
Aurora Cannabis (ACB) posted quarterly Cash from Investing Activities of -$979864.6 for Q1 2025, up 67.9% year-on-year from -$583608.4 in Q1 2024, and up 57.38% on a QoQ basis from -$2.3 million in Q4 2024.
Aurora Cannabis (ACB) Cash from Investing Activities (2017 - 2025) Analysis & Trends
Aurora Cannabis (ACB) has reported Cash from Investing Activities for 9 consecutive years, with -$979864.6 the latest figure, recorded in Q1 2025.
- Quarterly Cash from Investing Activities rose 67.9% year-over-year to -$979864.6 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was -$6.0 million (up 88.19% YoY) and the FY2026 annual result came in at -$52.7 million, down 517.41% from the prior year.
- Cash from Investing Activities climbed to -$979864.6 in Q1 2025 per ACB's latest filing, from -$2.3 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for ACB reached as high as $25.8 million in Q4 2021 and fell as low as -$62.6 million in Q3 2022.
- A 5-year average of -$10.0 million and a median of -$2.7 million in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2021 — Cash from Investing Activities soared 770.37% — and 2022, when it sank 324.38%.
- Year by year, Cash from Investing Activities stood at $25.8 million in 2021, then tumbled by 291.45% to -$49.5 million in 2022, then soared by 110.22% to $5.1 million in 2023, then sank by 145.45% to -$2.3 million in 2024, then surged by 57.38% to -$979864.6 in 2025.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$979864.6, -$2.3 million, and -$2.7 million for Q1 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.16 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.46 Bn | 30.52 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 23.13 Bn | 20.98 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.48 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.75 Bn | 16.43 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.60 Bn | 12.18 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Aurora Cannabis | 156.08 Mn | 70.84 Mn | 21.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -979,864.57 |
| Mar 31, 2025 | -979,864.57 |
| Dec 31, 2024 | -2.30 Mn |
| Dec 31, 2024 | -2.30 Mn |
| Sep 30, 2024 | -2.67 Mn |
| Sep 30, 2024 | -2.67 Mn |
| Jun 30, 2024 | -11,698.25 |
| Jun 30, 2024 | -11,698.25 |
| Mar 31, 2024 | -3.05 Mn |
| Mar 31, 2024 | -3.05 Mn |
| Dec 31, 2023 | 5.06 Mn |
| Dec 31, 2023 | 5.06 Mn |
| Sep 30, 2023 | -2.97 Mn |
| Sep 30, 2023 | -2.97 Mn |
| Dec 31, 2022 | -49.48 Mn |
| Dec 31, 2022 | -49.48 Mn |
| Sep 30, 2022 | -62.62 Mn |
| Sep 30, 2022 | -62.62 Mn |
| Jun 30, 2022 | -31.17 Mn |
| Jun 30, 2022 | -31.17 Mn |